web analytics
2.9 C
Munich
Wednesday, November 30, 2022

Latest Insights on Cocrystal Pharma Inc (OTCBB:COCP)

Cocrystal Pharma Inc (OTCBB:COCP) is trading strong here. The stock continues to hold its gains after the Company announced back in October that they were developed a new Ebola Screening Technology.

The recent upswing in price and change of momentum is welcomed by investors in the Company how have endured close to a year of steady downward drift from the $0.88 highs the stock made at the end of last year.

Cocrystal Pharma Inc (OTCBB:COCP) is a pharmaceutical company seeking to discover novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. Cocrystal Pharma employs unique technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. These technologies and our market-focused approach to drug discovery are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer.

Cocrystal has previously received strategic investments from Teva Pharmaceuticals, OPKO Health and The Frost Group. OPKO Health and The Frost Group together own approximately 48% of Cocrystal.

In August COCP reported financial results for the second quarter ended June 30, 2014. Select financial and operational highlights include:

To Find out the inside Scoop on COCP  Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

As described in the Form 10-Q, the Company had as of June 30, 2014, $9.8 million in cash and marketable securities, an increase of $8.8 million from December 31, 2013. Operating expenses for the three months ended June 30, 2014 were $1.4 million compared to $1.0 million for the same period in 2013. For the six months ended June 30, 2014 operating expenses were $2.9 million compared to $2.1 million for the same period in 2013.

On October 23 COCP announced that it has developed what it believes to be the first high-throughput screening technology for inhibitors of a key essential Ebola virus gene product.

According to Cocrystal Chief Scientist, Dr. Roger Kornberg, “We are very excited to have cloned the gene, purified and characterized its product, and integrated the gene product into our high-throughput platform. We believe we are the first group to have developed a novel screening methodology that can accurately identify inhibitors, which are potential drug candidates.”

Obviously this is massive news for COCP and represents a significant breakthrough for the Company which has been struggling since the name change from Biozone Pharmaceuticals, Inc. in April of this year.

We have a Monster Pick Coming. Subscribe Right Now!

Conclusion: COCP is exploding upwards after the Company announced they have developed a new Ebola Screening Technology. This represents a significant breakthrough for the Company; Ebola is spreading quickly in West Africa with over 10,000 ppl already infected and 5,000 dead. Recently the virus has landed on U.S soil turning up the heat that much more.

Currently trading at a $50 million market valuation COCP represents a compelling technical setup with significant news as catalyst. This is a Company that looks to be working hard behind the scenes and the stock clearly deserves to be on speculators watch lists and might just provide a spectacular trade opportunity in the coming weeks and months ahead!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in COCP either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.